title: The effects of betahistine in addition to epley maneuver in posterior canal benign paroxysmal positional vertigo.
abstract: OBJECTIVE
  The purpose of this study is to evaluate the effects of betahistine in addition to Epley maneuver on the quality of life of patients with posterior semicircular canal benign paroxysmal positional vertigo (BPPV) of the canalithiasis type.
  
  
  METHODS
  Double-blind, randomized, controlled clinical trial.
  
  
  METHODS
  Academic university hospital.
  
  
  METHODS
  Seventy-two patients were enrolled in the study. The first group was treated with Epley maneuver only. The second group received placebo drug 2 times daily for 1 week in addition to Epley maneuver, and the third group received 24 mg betahistine 2 times daily for 1 week in addition to Epley maneuver. The effectiveness of the treatments was assessed in each group as well as between them by analyzing and comparing data of 4 different vertigo symptom scales.
  
  
  RESULTS
  Epley maneuver, alone or combined with betahistine or placebo, was found to be very effective with a primary success rate of 86.2%. The symptoms were significantly reduced in group 3 patients overall, and those patients younger or older than 50 years of age who had hypertension, with symptom onset <1 month, and with attack duration of less than a minute did significantly better with the combination of betahistine 48 mg daily.
  
  
  CONCLUSIONS
  Betahistine in addition to Epley maneuver is more effective than Epley maneuver alone or combined with placebo with regard to improvement of symptoms in certain patients. However, future clinical studies covering more patients to investigate the benefit of medical treatments in addition to Epley maneuver are needed.
authors.affiliation: Dokuz Eylul University Medical Faculty, Department of Otolaryngology Head and Neck Surgery, Izmir, Turkey. alpin.guneri@deu.edu.tr
authors.forename: Enis Alpin
authors.initials: EA
authors.lastname: Guneri
authors.forename: Ozge
authors.initials: O
authors.lastname: Kustutan
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D065635:Benign Paroxysmal Positional Vertigo; D001621:Betahistine / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D026741:Physical Therapy Modalities; D011187:Posture / Q000502:physiology*; D012665:Semicircular Canals / Q000503:physiopathology*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage; D014717:Vertigo / Q000503:physiopathology / Q000628:therapy*; D055815:Young Adult
chemical_list: D014665:Vasodilator Agents; D001621:Betahistine